JNJoanna Narbutt

Joanna Narbutt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joanna Narbutt has a total of 85 co-authors. Here are the top co-authors by number of shared publications:

  • Aleksandra Lesiak

    Department of Dermatology, Paediatrics, and Oncologic Dermatology, Medical University of Lodz, Poland

    11 shared publications
  • Anna Sysa-Jedrzejowska

    From the Departments of Dermatology and Pediatrics and Laboratory of Immunodermatology, Medical University of Lodz, Lodz, Poland

    9 shared publications
  • Aleksandra Lesiak

    Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Pomorska Street 251, 92-213 Lodz, Poland

    5 shared publications
  • Adam Reich

    Department of Dermatology, Faculty of Medicine, Medical College, University of Rzeszow, Rzeszow, Poland

    3 shared publications
  • Agnieszka Owczarczyk-Saczonek

    Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, School of Medicine, University of Warmia and Mazury in Olsztyn, 10-719 Olsztyn, Poland

    3 shared publications
  • Anna Wozniacka

    Department of Dermatology and Venereology, Medical University of Lodz, Lodz, Poland

    3 shared publications

Latest Publications

  • Open Access

    Risankizumab Therapy for Moderate-to-Severe Psoriasis—A Multi-Center, Long-Term, Real-Life Study from Poland

    by Michał Adamczyk, Joanna Bartosińska, Dorota Raczkiewicz, Kinga Adamska, Zygmunt Adamski, Maria Czubek, Beata Kręcisz, Elżbieta Kłujszo, Aleksandra Lesiak, Joanna Narbutt, et al.

    The present multi-center, long-term, real-life study made an attempt to assess the efficacy of risankizumab in the treatment of moderate-to-severe plaque psoriasis. The study comprised 185 patients from 10 Polish dermatologic departments undergoing risankizumab treatment. The disease severity was measured using the Psoriasis Area and Severity Index (PASI) before the start of the risankizumab treatment and next at the defined timepoints, i.e., 4, 16, 28, 40, 52 and 96 weeks of treatment. The percentage of patients achieving PASI90 and PASI100 responses as well as the PASI percentage decrease at the defined timepoints were calculated, and correlations with clinical characteristics and therapeutic effect were analyzed. The number of patients evaluated at the defined timepoints was: 136, 145, 100, 93, 62, and 22 at 4, 16, 28, 40, 52 and 96 weeks of treatment, respectively. At 4, 16, 28, 40, 52 and 96 weeks, the PASI90 response was achieved in 13.2%, 81.4%, 87.0%, 86.0%, 88.7% and 81.8% of patients, whereas the PASI100 response was achieved in 2.9%, 53.1%, 67.0%, 68.8%, 71.0% and 68.2% of patients, respectively. Our study revealed a significant negative correlation between a decrease in the PASI and the presence of psoriatic arthritis as well as the patient’s age and duration of psoriasis at several timepoints throughout the observation period.


  • Open Access

    The Analysis of a Genome-Wide Association Study (GWAS) of Overweight and Obesity in Psoriasis

    by Anna Kisielnicka, Marta Sobalska-Kwapis, Dorota Purzycka-Bohdan, Bogusław Nedoszytko, Monika Zabłotna, Michał Seweryn, Dominik Strapagiel, Roman J. Nowicki, Adam Reich, Dominik Samotij, et al.

    There is evidence that the concomitance of psoriasis and obesity may originate from the interplay between multiple genetic pathways and involve gene–gene interactions. The aim of this study was to compare the genetic background related to obesity among psoriatic patients versus healthy controls by means of a Genome-Wide Association Study (GWAS). A total of 972 psoriatic patients and a total of 5878 healthy donors were enrolled in this study. DNA samples were genotyped for over 500,000 single nucleotide polymorphisms (SNPs) using Infinium CoreExome BeadChips (Illumina, San Diego, CA, USA). Statistical analysis identified eleven signals (p < 1 × 10−5) associated with BMI across the study groups and revealed a varying effect size in each sub-cohort. Seven of the alternative alleles (rs1558902 in the FTO gene, rs696574 in the CALCRL gene, as well as rs10968110, rs4551082, rs4609724, rs9320269, and rs2338833,) are associated with increased BMI among all psoriatic patients and four (rs1556519 in the ITLN2 gene, rs12972098 in the AC003006.7 gene, rs12676670 in the PAG1 gene, and rs1321529) are associated with lower BMI. The results of our study may lead to further insights into the understanding of the pathogenesis of obesity among psoriatic patients.


  • Open Access

    Chronic Plaque Psoriasis in Poland: Disease Severity, Prevalence of Comorbidities, and Quality of Life

    by Dorota Purzycka-Bohdan, Anna Kisielnicka, Monika Zabłotna, Bogusław Nedoszytko, Roman J. Nowicki, Adam Reich, Dominik Samotij, Justyna Szczęch, Dorota Krasowska, Joanna Bartosińska, et al.

    The epidemiology of psoriasis has not been widely assessed in Polish population so far. This study aimed to investigate psoriasis epidemiological situation by evaluating disease course and severity, management, comorbidities, environmental factors, and knowledge about this disorder among psoriatic patients in Poland. A cross-sectional cohort population-based study enrolled 1080 psoriatic patients and 1200 controls. The mean age of psoriasis onset was 27.6 years; 78.24% had type I psoriasis. Positive family history of psoriasis was reported in 44.81% of patients, whereas itch was reported in vast majority of patients (83.33%). Based on PASI score moderate psoriasis was the most common in studied group (mean 12.63 ± 9.33, range 0–67.2). The DLQI score (12.01 ± 7.41, range 0–30.0) indicated a very large effect of psoriasis on the quality of life. Hypertension was the most prevalent comorbidity (33.80%), followed by obesity (16.85%) and dyslipidemia (11.85%). Stress was the foremost cause of disease exacerbation (66.20%); however, infections (44.07%) and seasonal changes (45.09%) had also an impact on the course of psoriasis. Psoriatic patients were more often smokers (37.59%) vs. general population (27.50%; p < 0.0001). In conclusion, epidemiological studies help clinicians in better disease and patient understanding, which may translate into better management and patient compliance.


  • Open Access

    Phototherapy in Atopic Dermatitis

    by Aleksandra Lesiak, Magdalena Ciazynska, Joanna Narbutt

    Atopic dermatitis (AD) is an inflammatory, recurrent and chronic disease that occurs in 2–10% of the population. Therapy of AD could be divided into topical (corticosteroids, calcineurin inhibitors) and systemic (cyclosporine, methotrexate, azathioprine or biological treatment). Phototherapy is taken into consideration as a second-line treatment, when topical therapy is unsuccessful. We distinguish many types of phototherapy, e.g. narrowband UVB (311–313 nm), UVA-1 therapy (340–400 nm), UVA/B combination, UVA therapy plus 8-methoxypsoralens (PUVA), 308 nm excimer laser (EL) and blue light. Phototherapy is effective in many cases, whether in adults or in children. It should be remembered that during therapy possible side effects may occur. Among them the risk of carcinogenesis is the most severe.


  • Open Access

    Morphea – selected local treatment methods and their effectiveness

    by Joanna Narbutt, Agnieszka Hołdrowicz, Aleksandra Lesiak

    Localised scleroderma is an uncommon connective tissue disease of multifactorial aetiology occurring in the paediatric and adult population. It is relatively difficult to conduct any research on the subject of this disease entity treatment due to the low number of patients suffering from morphea, a tendency of the disease to remit spontaneously, and not yet well recognised aetiology. Hence, there has been developed no causal treatment of well-proven effectiveness, and schedules of symptomatic therapy are not yet clearly determined. The paper depicts most widely used topical treatment methods in morphea therapy, which due to minor risk of systemic adverse effects seem to be a beneficial therapeutic alternative. The main aim of this article was to analyse different topical treatment options used in localised scleroderma therapy and to indicate the most appropriate, safe, and effective one.


  • Open Access

    The effect of an emollient with benfothiamine and Biolin prebiotic on the improvement of epidermal skin function

    by Joanna Narbutt, Igor A. Bednarski, Aleksandra Lesiak

    Introduction : Complications of diabetes can damage internal organs and the skin. Diabetic skin, irritated and dry, is susceptible to skin infections. However little is known about influence of emollients on biophysical changes in skin during diabetes. Aim : To evaluate clinical skin...


  • ICOS Gene Polymorphism May Be Associated with Pemphigus

    by Joanna Narbutt, Aleksandra Lesiak, Izabela Klich, Jolanta Dorota Torzecka, Anna Sysa-Jedrzejowska, Wojciech Młynarski

    Background: Pemphigus is an autoimmune blistering disease mediated by circulating IgG autoantibodies directed against desmogleins 3 and/or 1. As pemphigus is a T cell–mediated disease, one may assume that genetically determined disregulation of costimulatory signal may be involved in its pathogenesis. Objective: The aim of the present study was to evaluate the relationship between polymorphisms in genes encoding costimulatory receptors, CTLA4 and ICOS, and pemphigus in the Polish population. Methods: The study included 54 patients with pemphigus: 40 with pemphigus vulgaris (PV) and 14 with pemphigus foliaceus (PF). Additionally, 176 healthy unrelated blood donors served as controls. +49A/G CTLA4 and IVS1+173 ICOS polymorphisms were identified using a modified polymerase chain reaction–restriction fragment-length polymorphism. Results: Analysis of the frequency of genotypes and alleles of +49A/G CTLA4 gene polymorphism showed no statistically significant differences between the PV and PF patients and the controls. The distribution of genotypes in IVS1+173 ICOS polymorphisms was significantly different in both PV ( p < .01) and PF ( p = .0004) patients when compared to controls. The carriers of the allele C were more frequent in PV or PF in comparison with the control group ( p < .001 for both groups). Conclusions: Our results suggest that genetically determined abnormal function of costimulatory receptors in T cells may be associated with the pathogenesis of pemphigus.


  • Suberythemal ultraviolet B radiation alters the expression of cell cycle-related proteins in the epidermis of human subjects without leading to photoprotection

    by J. Narbutt, M. Norval, M. Slowik-Rylska, C. Jochymski, W. Kozłowski, A. Sysa-Jedrzejowska, M. Rogowski-Tylman, A. Lesiak

    Background Deregulation of the cell cycle proteins is one of the critical factors leading to cutaneous carcinogenesis. Objectives To monitor the expression of cell cycle proteins in the epidermis of subjects after repeated exposure to ultraviolet (UV) B radiation, and to test for the development of photoprotection by subsequent irradiation with a single erythemal UVB dose. Methods A total of 26 healthy volunteers were divided into four groups: group 1 (n = 9) were given whole‐body UVB irradiation for 10 consecutive days with 0·7 minimal erythema dose (MED), group 2 (n = 9) were irradiated as in group 1 followed 24 h later by a single UVB dose of 3 MED on buttock skin, group 3 (n = 4) were irradiated with a UVB dose of 3 MED on buttock skin, and group 4 (n = 4) were not irradiated. Skin biopsies were collected 24 h after the final irradiation and stained for cyclins A, B1, D1, and p16, p18, p21, p27, p53, pRB, Bax and Bcl‐2. Results The expression of cyclin D1, p18 and p21 was significantly higher in groups 1 and 2 compared with the nonirradiated group 4 controls and, in group 2, the expression of pRB, p53 and Bax was also increased. In group 3, only p53 and Bax proteins were significantly elevated compared with group 4. The expression of cyclin D1, p16, p18, p27, pRB and Bcl‐2 was higher in group 2 compared with group 3. Conclusions Suberythemal UVB radiation was sufficient to cause changes in the expression of several epidermal cell cycle proteins. When tested by irradiation with a single erythemal UVB dose following the repeated exposures, no photoprotection against the UV‐induced alteration in cell cycle protein expression was apparent.


  • Open Access

    Serum Concentration of Interleukin‐6 Is Increased Both in Active and Remission Stages of Pemphigus Vulgaris

    by Joanna Narbutt, Jolanta Lukamowicz, Jarosław Bogaczewicz, Anna Sysa-Jedrzejowska, Jolanta Dorota Torzecka, Aleksandra Lesiak

    As most studies on pemphigus vulgaris (PV) pathogenesis concern its active stage, we aimed to evaluate the serum concentration of TNF‐α, IL‐1, and IL‐6 in PV patients in clinical remission. The study group consisted of sera from 19 PV patients in active stage and from 24 patients in clinical remission. 19 sera taken from healthy subjects served as the controls. Serum IL‐6 concentrations in PV active and PV remission group were significantly higher when compared to the controls (P < .05). In patients in active stage of PV, a significant correlation between serum IL‐1 and IL‐6 concentrations was found (rP = 0.46; P < .05). We also found a negative correlation between TNF‐α level and pemphigus antibodies titer in the patients from the remission group (rS = −0.47303; P < .02). Our data suggest that IL‐6 and TNF‐α may be involved in maintaining immunological disturbances in remission stage of PV.


  • Increased cyclooxygenase expression and thymine dimer formation after repeated exposures of humans to low doses of solar simulated radiation

    by Joanna Narbutt, Aleksandra Lesiak, Cezary Jochymski, Wojciech Kozlowski, Anna Sysa‐Jedrzejowska, Mary Norval

    Abstract:  The impact of repeated doses of solar simulated radiation (SSR) has not been evaluated, particularly to determine if photoadaptation and photoprotection develop over time. In this study, erythema, pigmentation, cyclooxygenase (COX)‐1 and 2 expression and thymine dimer (dTT) formation were evaluated in the skin of irradiated subjects of phototype II or III. Groups of 7–10 volunteers were whole‐body irradiated with a low dose of SSR on each of 10 consecutive days followed by a single erythemal ultraviolet B (UVB) dose on a small body area, or irradiated only with the single erythemal UVB dose on a small body area, or irradiated with the low dose of SSR on each of 30 consecutive days, or were unirradiated. Erythema and pigmentation were measured 24 h after the final SSR or UVB, and skin biopsies collected for the assessment of COX+ cells and dTT+ nuclei. The repeated SSR exposures induced a small increase in pigmentation without erythema, and were slightly protective against the erythemal effects of the subsequent high UVB dose. The number of COX‐1+ and 2+ cells increased as a result of 10‐days SSR and rose still further after 30‐days SSR, indicating that photoadaptation had not developed. The SSR exposures did not result in any protection against the further increase in COX‐1 and 2 expression caused by the erythemal UVB dose. In contrast, for dTT formation, the repeated SSR exposures led to a limited degree of both photoadaptation and photoprotection.